[Clinical trials with localized mitomycin instillation therapy for superficial urothelial bladder carcinoma].
105 patients with transitional cell carcinoma of the bladder, stage Tis, TA, T1 were treated by a local cytostatica therapy with Mitomycin C (MMC) after transurethral resection (TUR) of the bladder with the following purposes: 1. curative therapy of the carcinoma in situ 2. avoidance of tumor cell implantation from the TUR. After a follow up of 22,3 months this therapeutic concept seems to be of great promise because of its clearly reduced recurrence rate of a total of 12,4%. Side effects are slight. Nevertheless it must be pointed out, that any definitive statement can only be made after a longterm observation, especially by multicentric, controlled, randomized studies. MMC serum resorption studies with 19 patients, partly with reflux and TUR caused perforation of the bladder, showed that MMC instillation therapy (20 mg MMC/40 ml NaCl) immediately after resection did not lead to a systemic toxic concentration.
D000328:Adult; D000368:Aged; D002278:Carcinoma in Situ / Q000188:drug therapy / Q000601:surgery; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000601:surgery; D002986:Clinical Trials as Topic; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage* / Q000627:therapeutic use; D009367:Neoplasm Staging; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery
D008937:Mitomycins; D016685:Mitomycin
Klinische Erfahrungen mit der lokalen Mitomycin-Therapie oberflächlicher Urothelkarzinome der Harnblase.